Drilling with the beam of an electron microscope, scientists at ORNL precisely machined tiny electrically conductive cubes that can interact with light and organized them in patterned structures that confine and relay light’s electromagnetic signal.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.
Researchers working with Oak Ridge National Laboratory developed a new method to observe how proteins, at the single-molecule level, bind with other molecules and more accurately pinpoint certain molecular behavior in complex
Oak Ridge National Laboratory’s Center for Nanophase Materials Sciences contributed to a groundbreaking experiment published in Science that tracks the real-time transport of individual molecules.
After its long journey to Mars beginning this summer, NASA’s Perseverance rover will be powered across the planet’s surface in part by plutonium produced at the Department of Energy’s Oak Ridge National Laboratory.
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
If humankind reaches Mars this century, an Oak Ridge National Laboratory-developed experiment testing advanced materials for spacecraft may play a key role.
By automating the production of neptunium oxide-aluminum pellets, Oak Ridge National Laboratory scientists have eliminated a key bottleneck when producing plutonium-238 used by NASA to fuel deep space exploration.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.